Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma.

Kessler T, Baumeier A, Brand C, Grau M, Angenendt L, Harrach S, Stalmann U, Schmidt LH, Gosheger G, Hardes J, Andreou D, Dreischalück J, Lenz G, Wardelmann E, Mesters RM, Schwöppe C, Berdel WE, Hartmann W, Schliemann C.

Transl Oncol. 2018 Dec;11(6):1271-1282. doi: 10.1016/j.tranon.2018.08.004. Epub 2018 Aug 17.

2.

90 Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience.

Spukti EU, Schmidt LH, Schulze A, Schliemann C, Görlich D, Wardelmann E, Hartmann W, Lenz G, Berdel WE, Kerkhoff A.

Eur J Haematol. 2018 Oct;101(4):514-521. doi: 10.1111/ejh.13138. Epub 2018 Sep 3.

PMID:
29993147
3.

Stromal collagen type VI associates with features of malignancy and predicts poor prognosis in salivary gland cancer.

Angenendt L, Mikesch JH, Görlich D, Busch A, Arnhold I, Rudack C, Hartmann W, Wardelmann E, Berdel WE, Stenner M, Schliemann C, Grünewald I.

Cell Oncol (Dordr). 2018 Oct;41(5):517-525. doi: 10.1007/s13402-018-0389-1. Epub 2018 Jun 15.

PMID:
29949051
4.

AAA+ ATPases Reptin and Pontin as potential diagnostic and prognostic biomarkers in salivary gland cancer - a short report.

Mikesch JH, Hartmann W, Angenendt L, Huber O, Schliemann C, Arteaga MF, Wardelmann E, Rudack C, Berdel WE, Stenner M, Grünewald I.

Cell Oncol (Dordr). 2018 Jun 5. doi: 10.1007/s13402-018-0382-8. [Epub ahead of print]

PMID:
29873033
5.

Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer.

Mikesch JH, Schwammbach D, Hartmann W, Schmidt LH, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoennissen NH, Wardelmann E, Köhler G, Lenz G, Müller-Tidow C, Berdel WE, Arteaga MF.

Eur Respir J. 2018 Jul 11;52(1). pii: 1701637. doi: 10.1183/13993003.01637-2017. Print 2018 Jul.

PMID:
29853494
6.

Adjuvant chemotherapy-Radiotherapy-Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases.

Schliemann C, Kerkhoff A, Hesse P, Bröckling S, Hardes J, Streitbürger A, Andreou D, Gosheger G, Elges S, Wardelmann E, Hartmann W, Mesters R, Lenz G, Willich N, Kriz J, Eich H, Berdel WE, Kessler T.

PLoS One. 2018 May 22;13(5):e0197315. doi: 10.1371/journal.pone.0197315. eCollection 2018.

7.

High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia.

Steckel NK, Groth C, Mikesch JH, Trenschel R, Ottinger H, Kordelas L, Mueller-Tidow C, Schliemann C, Reicherts C, Albring JC, Silling G, Schmidt E, Berdel WE, Lenz G, Ditschkowski M, Beelen DW, Stelljes M.

Br J Haematol. 2018 Mar;180(6):840-853. doi: 10.1111/bjh.15137. Epub 2018 Feb 21.

PMID:
29468631
8.

Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.

Lengfelder E, Görlich D, Nowak D, Spiekermann K, Haferlach C, Krug U, Kreuzer KA, Braess J, Schliemann C, Lindemann HW, Horst HA, Schiel X, Flasshove M, Hecht A, Schnittger S, Schneider S, Wörmann B, Hofmann WK, Berdel WE, Bormann E, Sauerland C, Büchner T, Hiddemann W; German Acute Myeloid Leukemia Cooperative Group (AMLCG).

Eur J Haematol. 2018 Feb;100(2):154-162. doi: 10.1111/ejh.12994. Epub 2017 Dec 4.

PMID:
29114972
9.

CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.

Schmidt LH, Stucke-Ring J, Brand C, Schliemann C, Harrach S, Muley T, Herpel E, Kessler T, Mohr M, Görlich D, Kreuter M, Lenz G, Wardelmann E, Thomas M, Berdel WE, Schwöppe C, Hartmann W.

Lung Cancer. 2017 Nov;113:121-127. doi: 10.1016/j.lungcan.2017.09.013. Epub 2017 Sep 22.

PMID:
29110838
10.

Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.

Schmidt LH, Heitkötter B, Schulze AB, Schliemann C, Steinestel K, Trautmann M, Marra A, Hillejan L, Mohr M, Evers G, Wardelmann E, Rahbar K, Görlich D, Lenz G, Berdel WE, Hartmann W, Wiewrodt R, Huss S.

PLoS One. 2017 Oct 27;12(10):e0186280. doi: 10.1371/journal.pone.0186280. eCollection 2017.

11.

Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W.

PLoS One. 2017 Aug 9;12(8):e0183201. doi: 10.1371/journal.pone.0183201. eCollection 2017.

12.

An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

Angenendt L, Reuter S, Kentrup D, Benk AS, Neumann F, Hüve J, Martens AC, Schwöppe C, Kessler T, Schmidt LH, Sauer T, Brand C, Mikesch JH, Lenz G, Mesters RM, Müller-Tidow C, Hartmann W, Wardelmann E, Neri D, Berdel WE, Roesli C, Schliemann C.

Leukemia. 2018 Feb;32(2):510-519. doi: 10.1038/leu.2017.208. Epub 2017 Jun 30.

PMID:
28663580
13.

Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W.

PLoS One. 2017 Jun 12;12(6):e0177146. doi: 10.1371/journal.pone.0177146. eCollection 2017. Erratum in: PLoS One. 2017 Aug 9;12 (8):e0183201.

14.

Corrigendum: SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.

Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, Cinatl J Jr.

Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788a. No abstract available.

PMID:
28586337
15.

Weekly screening supports terminating nosocomial transmissions of vancomycin-resistant enterococci on an oncologic ward - a retrospective analysis.

Kampmeier S, Knaack D, Kossow A, Willems S, Schliemann C, Berdel WE, Kipp F, Mellmann A.

Antimicrob Resist Infect Control. 2017 May 16;6:48. doi: 10.1186/s13756-017-0206-z. eCollection 2017.

16.

Successful second allogeneic stem cell transplantation in a patient with T-lymphoblastic leukemia (T-ALL) relapsed as myeloid sarcoma.

Matern S, Schmidt E, Hartmann D, Schliemann C, Groth C, Lenz G, Hartmann W, Klapper W, Berdel W, Stelljes M.

Ann Hematol. 2017 Jul;96(7):1201-1203. doi: 10.1007/s00277-017-3000-3. Epub 2017 Apr 27. No abstract available.

PMID:
28451803
17.

RNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations.

Brabetz O, Alla V, Angenendt L, Schliemann C, Berdel WE, Arteaga MF, Mikesch JH.

Mol Ther Nucleic Acids. 2017 Mar 17;6:243-248. doi: 10.1016/j.omtn.2016.12.012. Epub 2017 Jan 12.

18.

Folding two lobes, you don't get a cup?

Mikesch JH, Schliemann C.

Blood. 2016 Sep 1;128(9):1309. doi: 10.1182/blood-2016-06-720169. No abstract available.

19.

SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.

Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, Cinatl J Jr.

Nat Med. 2017 Feb;23(2):250-255. doi: 10.1038/nm.4255. Epub 2016 Dec 19. Erratum in: Nat Med. 2017 Jun 6;23 (6):788.

PMID:
27991919
20.

PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.

Albring JC, Inselmann S, Sauer T, Schliemann C, Altvater B, Kailayangiri S, Rössig C, Hartmann W, Knorrenschild JR, Sohlbach K, Groth C, Lohoff M, Neubauer A, Berdel WE, Burchert A, Stelljes M.

Bone Marrow Transplant. 2017 Feb;52(2):317-320. doi: 10.1038/bmt.2016.274. Epub 2016 Nov 28. No abstract available.

PMID:
27892950
21.

Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years).

Pohlen M, Groth C, Sauer T, Görlich D, Mesters R, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Berdel WE, Stelljes M.

Bone Marrow Transplant. 2016 Nov;51(11):1441-1448. doi: 10.1038/bmt.2016.156. Epub 2016 Jun 13.

PMID:
27295269
22.

Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.

Stucke-Ring J, Ronnacker J, Brand C, Höltke C, Schliemann C, Kessler T, Schmidt LH, Harrach S, Mantke V, Hintelmann H, Hartmann W, Wardelmann E, Lenz G, Wünsch B, Müller-Tidow C, Mesters RM, Schwöppe C, Berdel WE.

Oncotarget. 2016 Dec 13;7(50):82458-82472. doi: 10.18632/oncotarget.12559.

23.

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.

Schliemann C, Gerss J, Wiebe S, Mikesch JH, Knoblauch N, Sauer T, Angenendt L, Kewitz T, Urban M, Butterfass-Bahloul T, Edemir S, Vehring K, Müller-Tidow C, Berdel WE, Krug U.

PLoS One. 2016 Oct 7;11(10):e0164499. doi: 10.1371/journal.pone.0164499. eCollection 2016.

24.

Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.

Pohlen M, Marx J, Mellmann A, Becker K, Mesters RM, Mikesch JH, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Krug U, Stelljes M, Karch H, Peters G, Gerth HU, Görlich D, Berdel WE.

Haematologica. 2016 Oct;101(10):1208-1215. Epub 2016 Jul 28.

25.

Thoracic Malignancies and Pulmonary Nodules in Patients under Evaluation for Transcatheter Aortic Valve Implantation (TAVI): Incidence, Follow Up and Possible Impact on Treatment Decision.

Schmidt LH, Vietmeier B, Kaleschke G, Schülke C, Görlich D, Schliemann C, Kessler T, Schulze AB, Buerke B, Kuemmel A, Thrull M, Wiewrodt R, Baumgartner H, Berdel WE, Mohr M.

PLoS One. 2016 May 12;11(5):e0155398. doi: 10.1371/journal.pone.0155398. eCollection 2016.

26.

Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.

Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen L, Maschmeyer G, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T.

Leukemia. 2016 Jun;30(6):1230-6. doi: 10.1038/leu.2016.25. Epub 2016 Feb 9.

PMID:
26859081
27.

Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC.

Schmidt LH, Kuemmel A, Schliemann C, Schulze A, Humberg J, Mohr M, Görlich D, Hartmann W, Bröckling S, Marra A, Hillejan L, Goletz S, Karsten U, Berdel WE, Spieker T, Wiewrodt R.

Lung Cancer. 2016 Feb;92:8-14. doi: 10.1016/j.lungcan.2015.11.019. Epub 2015 Nov 27.

PMID:
26775589
28.

NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.

Brand C, Schliemann C, Ring J, Kessler T, Bäumer S, Angenendt L, Mantke V, Ross R, Hintelmann H, Spieker T, Wardelmann E, Mesters RM, Berdel WE, Schwöppe C.

Oncotarget. 2016 Feb 9;7(6):6774-89. doi: 10.18632/oncotarget.6725.

29.

MN1-Fli1 oncofusion transforms murine hematopoietic progenitor cells into acute megakaryoblastic leukemia cells.

Wenge DV, Felipe-Fumero E, Angenendt L, Schliemann C, Schmidt E, Schmidt LH, Thiede C, Ehninger G, Berdel WE, Arteaga MF, Mikesch JH.

Oncogenesis. 2015 Dec 21;4:e179. doi: 10.1038/oncsis.2015.41.

30.

Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation.

Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M, Stegger L, Schäfers M, Groth C, Kessler T, Lenz G, Stelljes M, Berdel WE.

Bone Marrow Transplant. 2016 Mar;51(3):443-5. doi: 10.1038/bmt.2015.266. Epub 2015 Nov 9. No abstract available.

PMID:
26551782
31.

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.

Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, Grünewald I, Marra A, Schultheis AM, Wardelmann E, Müller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W.

PLoS One. 2015 Aug 27;10(8):e0136023. doi: 10.1371/journal.pone.0136023. eCollection 2015.

32.

Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR.

Brand C, Fröhlich M, Ring J, Schliemann C, Kessler T, Mantke V, König S, Lücke M, Mesters RM, Berdel WE, Schwöppe C.

Mol Pharm. 2015 Oct 5;12(10):3749-58. doi: 10.1021/acs.molpharmaceut.5b00508. Epub 2015 Aug 31.

PMID:
26310827
33.

Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor.

Brand C, Dencks S, Schmitz G, Mühlmeister M, Stypmann J, Ross R, Hintelmann H, Schliemann C, Müller-Tidow C, Mesters RM, Berdel WE, Schwöppe C.

J Ultrasound Med. 2015 Jul;34(7):1227-36. doi: 10.7863/ultra.34.7.1227.

PMID:
26112625
34.

Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature.

Börschel N, Schwöppe C, Zerbst C, Angenendt L, Kessler T, Klapper W, Giovannoni L, Elia G, Neri D, Berdel WE, Mesters RM, Schliemann C.

Leuk Res. 2015 Jul;39(7):739-48. doi: 10.1016/j.leukres.2015.04.005. Epub 2015 Apr 17.

PMID:
25934049
35.

Perioperative chemotherapy in gastroesophageal cancer. A retrospective monocenter evaluation of 42 cases.

Brehler AC, Hartmann W, Wiebe S, Kerkhoff A, Schliemann C, Palmes D, Senninger N, Lenze F, Ullerich H, Berdel WE, Kessler T.

PLoS One. 2015 Apr 9;10(4):e0122974. doi: 10.1371/journal.pone.0122974. eCollection 2015.

36.

Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman's disease.

Angenendt L, Kerkhoff A, Wiebe S, Mikesch JH, Rudat A, Wötzel F, Wenning C, Schliemann C, Kessler T, Schäfers M, Wardelmann E, Stelljes M, Berdel WE.

Ann Hematol. 2015 Jul;94(7):1241-3. doi: 10.1007/s00277-015-2353-8. Epub 2015 Mar 21. No abstract available.

PMID:
25791243
37.

Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.

Schliemann C, Gutbrodt KL, Kerkhoff A, Pohlen M, Wiebe S, Silling G, Angenendt L, Kessler T, Mesters RM, Giovannoni L, Schäfers M, Altvater B, Rossig C, Grünewald I, Wardelmann E, Köhler G, Neri D, Stelljes M, Berdel WE.

Cancer Immunol Res. 2015 May;3(5):547-56. doi: 10.1158/2326-6066.CIR-14-0179. Epub 2015 Feb 11.

38.

Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis.

Mohr M, Schliemann C, Biermann C, Schmidt LH, Kessler T, Schmidt J, Wiebe K, Müller KM, Hoffmann TK, Groll AH, Werner C, Kessler C, Wiewrodt R, Rudack C, Berdel WE.

Oncol Lett. 2014 Nov;8(5):1912-1918. Epub 2014 Aug 28.

39.

Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.

Persigehl T, Ring J, Bremer C, Heindel W, Holtmeier R, Stypmann J, Claesener M, Hermann S, Schäfers M, Zerbst C, Schliemann C, Mesters RM, Berdel WE, Schwöppe C.

Angiogenesis. 2014 Jan;17(1):235-46. doi: 10.1007/s10456-013-9391-4. Epub 2013 Oct 18.

PMID:
24136410
40.

Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.

Gutbrodt KL, Schliemann C, Giovannoni L, Frey K, Pabst T, Klapper W, Berdel WE, Neri D.

Sci Transl Med. 2013 Sep 4;5(201):201ra118. doi: 10.1126/scitranslmed.3006221.

41.

DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.

Mikesch JH, Kuhlmann M, Demant A, Krug U, Thoennissen GB, Schmidt E, Kessler T, Schliemann C, Pohlen M, Mohr M, Evers G, Köhler G, Wessling J, Mesters R, Müller-Tidow C, Berdel WE, Thoennissen NH.

Ann Hematol. 2013 Aug;92(8):1041-8. doi: 10.1007/s00277-013-1738-9. Epub 2013 Mar 27.

PMID:
23532626
42.

Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor.

Schwöppe C, Zerbst C, Fröhlich M, Schliemann C, Kessler T, Liersch R, Overkamp L, Holtmeier R, Stypmann J, Dreiling A, König S, Höltke C, Lücke M, Müller-Tidow C, Mesters RM, Berdel WE.

J Med Chem. 2013 Mar 28;56(6):2337-47. doi: 10.1021/jm301669z. Epub 2013 Mar 15.

PMID:
23496322
43.

Analysis of a novel highly metastatic melanoma cell line identifies osteopontin as a new lymphangiogenic factor.

Liersch R, Shin JW, Bayer M, Schwöppe C, Schliemann C, Berdel WE, Mesters R, Detmar M.

Int J Oncol. 2012 Oct;41(4):1455-63. doi: 10.3892/ijo.2012.1548. Epub 2012 Jul 6.

44.

Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients.

Liersch R, Gerss J, Schliemann C, Bayer M, Schwöppe C, Biermann C, Appelmann I, Kessler T, Löwenberg B, Büchner T, Hiddemann W, Müller-Tidow C, Berdel WE, Mesters R.

Blood. 2012 May 31;119(22):5215-20. doi: 10.1182/blood-2011-11-389692. Epub 2012 Apr 17.

45.

The accessible cerebral vascular proteome in a mouse model of cerebral β-amyloidosis.

Roesli C, Fugmann T, Borgia B, Schliemann C, Neri D, Jucker M.

J Proteomics. 2011 Apr 1;74(4):539-46. doi: 10.1016/j.jprot.2011.01.010. Epub 2011 Jan 22.

PMID:
21262399
46.

Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.

Dreischalück J, Schwöppe C, Spieker T, Kessler T, Tiemann K, Liersch R, Schliemann C, Kreuter M, Kolkmeyer A, Hintelmann H, Mesters RM, Berdel WE.

Int J Oncol. 2010 Dec;37(6):1389-97.

PMID:
21042706
47.

The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma.

Frey K, Schliemann C, Schwager K, Giavazzi R, Johannsen M, Neri D.

J Urol. 2010 Dec;184(6):2540-8. doi: 10.1016/j.juro.2010.07.030. Epub 2010 Oct 28.

PMID:
21030045
48.

Antibody-based vascular tumor targeting.

Schliemann C, Neri D.

Recent Results Cancer Res. 2010;180:201-16. doi: 10.1007/978-3-540-78281-0_12. Review.

PMID:
20033385
49.

A proteomic approach for the identification of vascular markers of liver metastasis.

Borgia B, Roesli C, Fugmann T, Schliemann C, Cesca M, Neri D, Giavazzi R.

Cancer Res. 2010 Jan 1;70(1):309-18. doi: 10.1158/0008-5472.CAN-09-2939. Epub 2009 Dec 8.

50.

In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy.

Schliemann C, Roesli C, Kamada H, Borgia B, Fugmann T, Klapper W, Neri D.

Blood. 2010 Jan 21;115(3):736-44. doi: 10.1182/blood-2009-08-239004. Epub 2009 Nov 10.

Supplemental Content

Loading ...
Support Center